{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:42:10Z","timestamp":1788964930721,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005088","name":"Beijing Municipal Health Commission","doi-asserted-by":"publisher","award":["2024-1-4052"],"award-info":[{"award-number":["2024-1-4052"]}],"id":[{"id":"10.13039\/501100005088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017542","name":"Beijing Hospital","doi-asserted-by":"publisher","award":["BJ-2025-141"],"award-info":[{"award-number":["BJ-2025-141"]}],"id":[{"id":"10.13039\/501100017542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020084","name":"Centre for Future Health, University of York","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020084","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.eprac.2025.12.018","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T23:50:29Z","timestamp":1767052229000},"page":"598-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of Drug Induced Thyroid Dysfunction Risk Using the United States Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7574-119X","authenticated-orcid":false,"given":"Ruixue","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9461-0453","authenticated-orcid":false,"given":"Pengfei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2025.12.018_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2024.108773","article-title":"Air pollution exposure, accelerated biological aging, and increased thyroid dysfunction risk: evidence from a nationwide prospective study","volume":"188","author":"Liang","year":"2024","journal-title":"Environ Int"},{"issue":"3","key":"10.1016\/j.eprac.2025.12.018_bib2","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.identj.2025.02.028","article-title":"Thyroid dysfunction and oral lichen planus: evidence from two-sample Mendelian randomization analysis","volume":"75","author":"Xie","year":"2025","journal-title":"Int Dent J"},{"issue":"9","key":"10.1016\/j.eprac.2025.12.018_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.advnut.2025.100471","article-title":"Association of mild-to-moderate iodine deficiency with thyroid Function-A systematic review and meta-analysis","volume":"16","author":"Aarsland","year":"2025","journal-title":"Adv Nutr"},{"issue":"21","key":"10.1016\/j.eprac.2025.12.018_bib4","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1080\/10408398.2024.2386633","article-title":"Balancing the benefits and risks of China's national salt iodization policy over 30 years using disability-adjusted life years (DALYs): a systematic review and meta-analysis","volume":"65","author":"Chen","year":"2025","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"5","key":"10.1016\/j.eprac.2025.12.018_bib5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1089\/thy.2016.0635","article-title":"Multiple nutritional factors and the risk of Hashimoto's Thyroiditis","volume":"27","author":"Hu","year":"2017","journal-title":"Thyroid"},{"issue":"9225","key":"10.1016\/j.eprac.2025.12.018_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(00)02490-9","article-title":"The importance of selenium to human health","volume":"356","author":"Rayman","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.eprac.2025.12.018_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2025.12.018_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e21694","article-title":"Thyroid dysfunction associated with iodine-contrast media: a real-world pharmacovigilance study based on the FDA adverse event reporting system","volume":"9","author":"Huang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.eprac.2025.12.018_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/CLEP.S494215","article-title":"Investigating drug-induced thyroid dysfunction adverse events associated with non-selective RET multi-kinase inhibitors: a pharmacovigilance analysis utilizing FDA adverse event reporting system data","volume":"17","author":"Meng","year":"2025","journal-title":"Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.eprac.2025.12.018_bib10","doi-asserted-by":"crossref","first-page":"E332","DOI":"10.1002\/ajh.25997","article-title":"BCR-ABL1 tyrosine kinase inhibitor-associated thyroid dysfunction: a review of cases reported to the FDA Adverse event reporting system and published in the literature","volume":"95","author":"Patel","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.eprac.2025.12.018_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1231320","article-title":"Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.eprac.2025.12.018_bib12","first-page":"394","article-title":"Drug-induced hypothyroidism","volume":"77","author":"Rizzo","year":"2017","journal-title":"Medicina (B Aires)"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.018_bib13","article-title":"Thyroid dysfunction and mortality in cardiovascular hospitalized patients","volume":"13","author":"Frankel","year":"2024","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.018_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13256-018-1708-x","article-title":"Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report","volume":"12","author":"Yonezaki","year":"2018","journal-title":"J Med Case Rep"},{"issue":"4","key":"10.1016\/j.eprac.2025.12.018_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.eprac.2025.12.018_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.989032","article-title":"Post-marketing safety of immunomodulatory drugs in multiple myeloma: a pharmacovigilance investigation based on the FDA adverse event reporting system","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"6-07","key":"10.1016\/j.eprac.2025.12.018_bib17","first-page":"469","article-title":"Age and sex influence thyroid hormone effects in target tissues with organ-specific responses","volume":"128","author":"Kerp","year":"2020","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.018_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/bdi.12150","article-title":"Gender differences in thyroid system function: relevance to bipolar disorder and its treatment","volume":"16","author":"Bauer","year":"2014","journal-title":"Bipolar Disord"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.018_bib19","first-page":"327","article-title":"Amiodarone and thyroid dysfunction","volume":"61","author":"Medi\u0107","year":"2022","journal-title":"Acta Clin Croat"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.018_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5603\/EP.2015.0025","article-title":"Amiodarone and the thyroid","volume":"66","author":"Jabrocka-Hybel","year":"2015","journal-title":"Endokrynol Pol"},{"issue":"6","key":"10.1016\/j.eprac.2025.12.018_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14341\/probl13267","article-title":"[Type 2 amiodarone-induced thyrotoxicosis: efficacy of glucocorticoid therapy, a retrospective analysis]","volume":"69","author":"Ermolaeva","year":"2024","journal-title":"Probl Endokrinol (Mosk)"},{"key":"10.1016\/j.eprac.2025.12.018_bib22","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.945444","article-title":"Enhanced differentiation of amiodarone-induced thyrotoxicosis types using semi-quantitative 99mTc-MIBI uptake analysis: a pilot study","volume":"30","author":"Fischer","year":"2024","journal-title":"Med Sci Monit"},{"issue":"8","key":"10.1016\/j.eprac.2025.12.018_bib23","first-page":"514","article-title":"AMIODARONE-INDUCED thyrotoxicosis - risk factors and predictors of outcome: a retrospective study","volume":"160","author":"Khalaili","year":"2021","journal-title":"Harefuah"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.018_bib24","first-page":"32","article-title":"Anticancer drug-induced thyroid dysfunction","volume":"16","author":"Bhattacharya","year":"2020","journal-title":"Eur Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2025.12.018_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101660","article-title":"Immune checkpoint inhibitor-related thyroid dysfunction","volume":"36","author":"Iwama","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"21","key":"10.1016\/j.eprac.2025.12.018_bib26","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/jnci\/djr373","article-title":"Thyroid dysfunction from antineoplastic agents","volume":"103","author":"Hamnvik","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2025.12.018_bib27","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s10555-012-9355-y","article-title":"Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma","volume":"31","author":"M\u00e9ndez-Vidal","year":"2012","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"10.1016\/j.eprac.2025.12.018_bib28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3109\/0284186X.2012.752579","article-title":"Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis","volume":"52","author":"Funakoshi","year":"2013","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.018_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/PPO.0000000000000186","article-title":"Managing adverse events with immune checkpoint agents","volume":"22","author":"Dadu","year":"2016","journal-title":"Cancer J"},{"issue":"11","key":"10.1016\/j.eprac.2025.12.018_bib30","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2025.12.018_bib31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.018_bib32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves' disease","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.eprac.2025.12.018_bib33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","article-title":"Thyroid disorders induced by checkpoint inhibitors","volume":"19","author":"Ferrari","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"10.1016\/j.eprac.2025.12.018_bib34","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.3390\/cancers12123586","article-title":"Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.eprac.2025.12.018_bib35","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1210\/jc.2018-00359","article-title":"Alemtuzumab-Induced thyroid dysfunction exhibits distinctive clinical and immunological features","volume":"103","author":"Pariani","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.018_bib36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/jc.2013-2201","article-title":"Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Daniels","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.018_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/imcb.1003","article-title":"Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells","volume":"96","author":"Sasidharan Nair","year":"2018","journal-title":"Immunol Cell Biol"},{"issue":"4","key":"10.1016\/j.eprac.2025.12.018_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.64719\/pb.4501","article-title":"Ultrasonically determined thyroid volume in individuals with bipolar disorder on lithium prophylaxis compared with healthy controls","volume":"54","author":"Bhasin","year":"2024","journal-title":"Psychopharmacol Bull"},{"issue":"9","key":"10.1016\/j.eprac.2025.12.018_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291482","article-title":"Under-reporting of adverse drug reactions: surveillance system evaluation in Ho Municipality of the Volta Region, Ghana","volume":"18","author":"Buabeng","year":"2023","journal-title":"PLoS One"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25013473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25013473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:59:07Z","timestamp":1778817547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25013473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1530891X25013473"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.12.018","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of Drug Induced Thyroid Dysfunction Risk Using the United States Food and Drug Administration Adverse Event Reporting System","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}